Posts

Genentech lays off 103 as part of gRED rethink, advances with $490M breast cancer collaboration

on

Genentech executes another round of layoffs, with 3 VPs axed

on

Who pays the best (and worst) in biopharma? A look at typical employee salaries

on

FDA Approves FoundationOne Liquid CDx as Companion Diagnostic for Itovebi (Inavolisib) in HR‑Positive, HER2‑Negative Breast Cancer with PIK3CA Mutation

on

White House Adds AbbVie's Humira to TrumpRx at 86% Discount Alongside Biosimilars and Other Drugs

on

Genentech Halts Emugrobart Development in Rare Genetic Muscle Diseases, Raising Concerns for Obesity Trials

on

SanegeneBio Licenses RNAi Program to Genentech for $200M Upfront and Up to $1.5B in Milestones

on

Exclusive: Charles Fuchs departs Roche to become Chief Medical Officer at Tubulis, steering ADC pipeline after $401M Series C

on

Roche's Patent License Deal with Structure Therapeutics for CT-996 Obesity Drug

on

Drugmakers Push US Expansion After Trump’s 100% Pharma Tariff Threat

on

Genentech Names Zoë Harris Lazarre as New Chief Marketing Officer as Erica Taylor Moves to Roche Role

on

Genentech (Roche) Signs $420 Million Deal With OMass Therapeutics for Preclinical IBD Program

on

Genentech's $700M North Carolina Plant and Telix’s FDA CRL Update

on

Genentech to End $2B Cell Therapy Collaboration with Adaptive Biotechnologies

on

Bicycle Therapeutics Lays Off 25% of Workforce After Genentech Collaboration Ends

on

FDA Rejects Roche’s Columvi for Earlier-Line Diffuse Large B-Cell Lymphoma

on

Genentech's Kristin Bittenbender Named BIO Board Chair Amid Industry Challenges

on

Recursion and Genentech Announce Significant Staff Layoffs in 2025

on

Genentech Lays Off 143 Employees as Part of Ongoing Cuts by Roche in Bay Area

on

FDA Advisory Committee Splits Votes on Genentech and J&J Cancer Drugs

on